Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion
By LabMedica International staff writers Posted on 24 Nov 2014 |
The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.14 billion for 2013, up from USD 910 million the previous year.
Kalorama noted that cancer CDx is an area increasingly focused on personalized approaches. “Novel biomarkers and subsequent companion diagnostics have the potential to transform the cancer treatment model from a one-size-fits-all approach to a personalized approach,” said report author Mary Ann Crandall. CDx increase the probability of clinical success by selectively identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes by determining which patients will respond well to therapy. CDx can also decrease costs – not only by identifying the patient population most likely benefit from the therapy but also by ruling out therapies not likely to be effective.
“In the past, each individual company would develop its own product, many times at great risk and expense,” said Ms. Crandall, “In many cases, it was viewed by industry participants as too risky to devote resources towards the development of a test that may never be used.”
The growing interest in CDx is fueling many novel partnerships between big pharma and diagnostic companies, such that co-development deals have taken center stage. In 2010 there were approximately 25 big pharma and diagnostic deals, up from 19 in 2009 and only 7 in 2008. That number has increased to over 50 since 2011 with oncology as the primary area of companion diagnostic licensing and/or partnership deals in recent years. The majority of partnerships have been with established diagnostic players such as Roche and Abbott, but there seems to be a recent shift toward specialized diagnostic companies, as seen in the Eli Lilly and PrimeraDx partnership. Most partnerships have been exclusive for a limited time period, providing stability for the diagnostic company and assuring it will be the first to market with its diagnostic, justifying the investment.
The Kalorama report has also identified the best disease markets for CDx approaches.
Related Links:
Kalorama Information
Companion Diagnostic Markets report
Kalorama noted that cancer CDx is an area increasingly focused on personalized approaches. “Novel biomarkers and subsequent companion diagnostics have the potential to transform the cancer treatment model from a one-size-fits-all approach to a personalized approach,” said report author Mary Ann Crandall. CDx increase the probability of clinical success by selectively identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes by determining which patients will respond well to therapy. CDx can also decrease costs – not only by identifying the patient population most likely benefit from the therapy but also by ruling out therapies not likely to be effective.
“In the past, each individual company would develop its own product, many times at great risk and expense,” said Ms. Crandall, “In many cases, it was viewed by industry participants as too risky to devote resources towards the development of a test that may never be used.”
The growing interest in CDx is fueling many novel partnerships between big pharma and diagnostic companies, such that co-development deals have taken center stage. In 2010 there were approximately 25 big pharma and diagnostic deals, up from 19 in 2009 and only 7 in 2008. That number has increased to over 50 since 2011 with oncology as the primary area of companion diagnostic licensing and/or partnership deals in recent years. The majority of partnerships have been with established diagnostic players such as Roche and Abbott, but there seems to be a recent shift toward specialized diagnostic companies, as seen in the Eli Lilly and PrimeraDx partnership. Most partnerships have been exclusive for a limited time period, providing stability for the diagnostic company and assuring it will be the first to market with its diagnostic, justifying the investment.
The Kalorama report has also identified the best disease markets for CDx approaches.
Related Links:
Kalorama Information
Companion Diagnostic Markets report
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance